Overview and Mission
Agensys, Inc., an affiliate of Astellas Pharma Inc., specializes in developing a pipeline of therapeutic fully human monoclonal antibodies (mAbs) to treat cancer. The mAb product pipeline is generated by Agensys’ diverse portfolio of proprietary, clinically relevant targets that encompass unmet clinical needs in cancer. Multiple programs are currently undergoing Phase I and Phase II Clinical Trials.
Agensys has full capabilities to generate, develop and manufacture antibody products. The company has been in operation since 1997 and was acquired by Astellas in December 2007. Agensys has over 200 employees, and is located in Santa Monica, California.
Our mission is to develop novel monoclonal antibodies and monoclonal antibody-drug conjugates (ADCs) to treat cancer and provide novel therapeutics for unmet medical needs.